Sudden cardiac death (SCD) due to recurrent ventricular tachycardia is an important clinical
sequela in patients with structural heart disease. As a result, ventricular tachycardia (VT) has …

Sudden cardiac death due to ventricular arrhythmias remains the most common cause of
death in developed nations. Implantable cardioverter defibrillators have been shown to …

With technological and mechanistic advancements in recent years, catheter ablation of
ventricular tachycardia has evolved to be a more upstream therapy. However, individual …

The treatment strategy for ventricular tachycardia (VT) is guided by patient symptoms, the
risk of sudden death estimated by VT mechanism and underlying cardiac structure, and the …

Although implantable cardioverter-defibrillators positively affect survival in patients at
increased risk for arrhythmic sudden cardiac death, quality of life can be negatively affected …

Ventricular tachycardia (VT) is one of the major causes of sudden cardiac death (SCD). In
general, VT could be managed with antiarrhythmic drugs (AADs) therapy, catheter ablation …

In patients with structural heart disease, ventricular tachycardia (VT) worsens the clinical
condition and may severely affect the short-and long-term prognosis. Several therapeutic …

Background Ventricular tachycardia (VT) causes significant morbidity and mortality.
Implantable cardioverter‐defibrillator shocks terminate VT but confer a significant morbidity …

Ventricular tachycardia is a potentially life-threatening arrhythmia associated with an overall
high morbi-mortality, particularly in patients with structural heart disease. Despite their …

Catheter ablation of ventricular tachycardia (VT) has evolved in recent years, especially in
patients with ischemic heart disease. Data from prospective studies show that VT catheter …